Ondas Stock Up 261% in a Year: Should Investors Buy, Hold or Sell?

Zevra plunges on EU snub for rare disease therapy

Berkshire Hathaway's Cash Pile Now Earns More in a Year Than Most S&P 500 Companies Report in Total Profit. Here's the Math.

NanoViricides announces $3.8M registered direct offering; shares down

FangDD receives Nasdaq notification